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Abstract
Autoimmune polyglandular syndromes (APS) consist of a variety of endocrine and non-endocrine disorders. The syndromes are complex 
and their occurrence in life does not follow any pattern. Early detection of such disorders may prevent many serious clinical consequences 
which are usually a result of delayed diagnosis. 
We present the case of a female patient whose clinical symptoms very strongly suggested APS, however neither autoimmune background 
except elevated anti-thyroid peroxidase and anti-thyroglobulin antibodies of multiglandular deficiency, nor critical mutations in the AIRE 
gene have been confirmed or detected, yet we identified five polymorphisms and two mutations in exon1 of gene AIRE during 12 years 
of observation and treatment. (Endokrynol Pol 2014; 65 (6): 514–518)
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Streszczenie 
Zespoły autoimmunologicznej niewydolności wielogruczołowej (APS) składają się z różnych zaburzeń, zarówno endokrynnych, jak 
i nieendokrynnych. Zespoły te są złożone i występują z różnymi objawami. Wczesne wykrycie zaburzeń może zapobiec wielu poważ-
nym skutkom klinicznym, które są zazwyczaj wynikiem opóźnionego rozpoznania. W pracy przedstawiono przypadek pacjentki, której 
objawy kliniczne przemawiają za zespołem autoimmunologicznej niewydolności wielogruczołowej. W ciągu 12 lat obserwacji i leczenia, 
autoimmunologiczne tło, z wyjątkiem stwierdzenia podwyższonego miana przeciwciał przeciw peroksydazie i przeciw tyreoglobulinie, 
nie zostało potwierdzone, podobnie jak krytyczna mutacja w genie AIRE. U pacjentki zidentyfikowano 5 polimorfizmów i 2 mutacje 
w eksonie 1 genu AIRE. (Endokrynol Pol 2014; 65 (6): 514–518)
Słowa kluczowe: autoimmunologiczna niewydolność wielogruczołowa; niedoczynność przytarczyc; niewydolność jajników; niedoczynność 
przysadki; gen AIRE 
Abbreviations:
APS — autoimmune polyglandular syndromes
APECED — autoimmune polyendocrinopathy candidi-
asis ectodermal dystrophy
TSH — thyrotropin
PTH — parathyroid hormone
ACTH — adrenocorticotropic hormone
aTPO — anti-thyroid peroxidase antibody
aTG — anti-thyroglobulin antibody
HbA1c — glycated haemoglobin
Anti-GAD — anti-glutamic acid decarboxylase antibody
GH — growth hormone
LH — luteinising hormone
FSH — follicle stimulating hormone
ICA — islet cell antibodies
IAA — insulin autoantibodies
CT — computed tomography
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Introduction
Autoimmune polyglandular syndromes (APS) are the 
most common cause of multiglandular insufficiency 
not associated with pituitary dysfunction. A variety 
of genetic alterations have been observed in patients 
diagnosed with APS. The components of APS are vari-
ous and include endocrinopathies and non-endocrine 
autoimmune disorders. APS can be classified into three 
major types (Table I) [1–4]. 
Autoimmune polyglandular syndromes type I is 
a monogenic disorder associated with mutations in 
AIRE gene (autoimmune regulator) which are fre-
quently observed in autoimmune diseases [2, 5]. This 
gene, located on chromosome 21q22.3, covers 11.9 kb 
and contains 14 exons. AIRE encodes the 545 amino-
acid (58-kD) nuclear protein. The presence of two 
zinc-finger motives (PHD-finger) suggests that AIRE 
protein belongs to the group of transcription factors. 
To date, 52 different mutations within the AIRE gene 
have been identified as causative alterations in several 
autoimmune endocrine disorders. Although these mu-
tations are spread throughout the whole coding region 
of the gene, hotspot mutations have been found in 
exons 6 and 8. 
Clinical symptoms of APS type II usually appear 
later in life. APS II has been proven to be associated 
with specific HLA antigens [2]. 
APS III is probably inherited in an autosomal 
dominant manner with incomplete penetrance. The 
first clinical symptoms usually develop in middle-aged 
patients.
Case report
The patient is an 18-year-old girl, under our care since 
the age of six (Table II). She was born at term with 
normal weight and length. No abnormalities were 
observed in the neonatal period and her parents are 
healthy. The first symptom — tetany — occurred at 
the age of four and was initially treated as epilepsy. 
However, at the time of presentation, the levels of 
calcium, ionised calcium and PTH were suggestive of 
hypoparathyroidism. The tests showed normal TSH 
and fT4, fT3 levels. The function of adrenal glands, lev-
els of autoantibodies, glucose and HbA1c were normal 
Table I. Disorders in types I and II Autoimmune Polyglandular Syndromes compared to our patient’s characteristics
Tabela I. Zaburzenia w APS I oraz APS II w porównaniu z zaburzeniami stwierdzanymi u opisywanej pacjentki
APS I Our Patient APS II Our Patient
Main symptoms Candidiasis – Addison’s disease –
Hypoparathyroidism + Type I diabetes –
HbA1c 5.3%, a/GAD < 5.0 IU/mL
Addison’s disease – Hypothyroidism aTPO 25.5 IU/mL N 
aTG 19.8 IU/mL N
Concomitant 
endocrinopathies
Type I diabetes –
HbA1c 5.3%, anti-GAD < 5.0 IU/mL
Hypoparathyroidism +
Hypogonadism + Hypogonadism 
Hypergonadotropic
+
Hypopituitarism + Hypopituitarism +
Hypothyroidism + 
aTPO 25.5 IU/mL N 
aTG 19.8 IU/mL N
Concomitant 
nonendocrine disorders
Vitiligo + Vitiligo +
Alopecia + Alopecia +
Hepatitis – Coeliac disease –
a/endomysium (tTG) < 2 RU/mL
Pernicious anaemia – Pernicious anaemia –
Malabsorption –
Myasthenia gravis –
Connective tissue 
disease
+
APS I — Autoimmune Polyglandular Syndrome type I; APS II — Autoimmune Polyglandular Syndrome type II
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(Table I). CT of the head was normal. Consequently, no 
more tremors were observed. The antiepileptic treat-
ment was discontinued and supplementary treatment 
was initiated. The bone age at that point was 4.5 years. 
An ophthalmologic abnormality — cataract — was 
observed in both eyes. 
One year later, progressive alopecia was observed 
in the patient, involving the scalp, eyebrows, eyelashes 
and the hair on the trunk. At the same time, the tests 
revealed thyroid insufficiency, but the antibodies level 
remained normal. A supplementary therapy of L-thy-
roxin was initiated and the thyroid function normalised.
Additionally, at the age of nine, vitiligo on the limbs 
and trunk was first observed.
Due to short stature and delayed bone age, con-
firmed by incorrect levels of GH (GH max 4.55 ng/mL) 
in the glucagon and L-dopa stimulation and noctur-
nal secretion tests, the patient was diagnosed with 
somatothropic hypopituitarism. MRI of the pituitary 
gland showed no abnormalities. Since the age of 11, 
the patient has been receiving 0.1 IU/kg of growth 
hormone daily. 
Before the initiation of GH therapy, the level of LH 
was normal while the FSH was high and oestradiol — 
low. Despite the revelation of normal female karyotype 
(46, XX), in the examination at the age of 12, the Tanner 
stage was I and no hair was present on the patient’s 
body (alopecia totalis).
The patient’s height increased by 14.3 cm during the 
first 24 months of GH therapy, but the bone age was 
delayed. At the age of 13, levels of gonadotropins were 
higher while those of oestradiol was lower than normal 
for this age. No pathology was observed in the pelvis ul-
trasound examination. Control MRI of the pituitary gland 
remained normal and the Tanner stage was unchanged. 
Due to the short period of GH treatment, the induction 
of oestrogen therapy was postponed. Function of adrenal 
gland remained normal in repeated tests. Also, the glucose 
curve, HbA1c, anti-GAD, ICA and IAA levels were normal 
in consecutive tests repeated annually. 
Table II. Laboratory data during the 12 years of patient observation 
Tabela II. Badania laboratoryjne w czasie 12-letniej obserwacji pacjentki
 At the time of diagnosis, 
age 6
Before initiating GH 
therapy, age 11
During GH therapy, age 15 Last examination, age 18
Height [cm] 106.5 126.3 151.7 154.7
Weight [kg] 16.6 24 33.3 37
Velocity of height [cm/year] 3.8 7.1 1
Bone age (years) 4.5 9 13 15
TSH [mIU/mL]
fT4
fT3 [pmol/mL]
aTPO [IU/mL] 
aTG [IU/mL]
3.53
1.0 pg/mL
3.5
< 10
< 10
1.88
1.61 pg/mL
4.27
25.5
19.8
2.58
16.6 pmol/L
3.5
328
> 1000
1,61
17.4 pmol/L
3.27
71
385
PTH [pg/mL] 1 [12–72]  < 3 5 6.19
LH [ mIU/mL] – 3.54 33.5 < 0.1
FSH [mIU/mL] – 44 104 0,559
Oestradiol [pg/mL] – < 20 31.1 33,6
Anti-adrenal antibodies Negative Negative Negative Negative
Cortisol profile Normal Normal Normal Therapy of 
methyloprednisolone
ACTH [pg/mL]  35 25 20 8,09
HbA1c (range) Normal Normal Normal Normal
anti-GAD [IU/mL] Negative Negative Negative Negative
ICA Negative Negative Negative Negative
IAA Negative Negative Negative Negative
Anti-endomysial antibodies Negative Negative Negative Negative
ANA antibodies  – – Negative Negative
cANCP] antibodies [RU/mL] – – 7.2 8 
pANCP antibodies [RU/mL] – – < 2.0 < 2.0 
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In the same year, conjunctivitis and keratitis were 
observed, while the IgE level was normal. The control 
levels of antibodies and liver function were still within 
normal limits. 
At age 15, the patient presented with new symp-
toms: evanescent skin rash, fever and myalgia. After 
excluding an infectious aetiology, connective tissue 
disease was diagnosed in the Rheumatology Depart-
ment for Children (Table II). The patient was started 
on methylprednisolone with good clinical response. 
Currently, she receives the following medications: 
L-thyroxine, methylprednisolone, alfacalcidol, oestro-
gen and progesterone. She has so far not presented 
with another clinical symptom.
A genetic consultation was performed as part of the 
work-up (Wroclaw Medical University and Institute 
of Physiology and Pathology of Hearing). Cytogenetic 
analysis was done on GTG and CBG-banded peripheral 
blood lymphocyte chromosomes, following the stand-
ard protocols and revealed normal female karyotype. 
Molecular analysis was performed on DNA extracted 
from the peripheral blood lymphocytes. All exons of 
the AIRE gene were amplified by the polymerase chain 
reaction technique using previously described primers 
(Table III) [6]. Direct sequencing of all coding exons of 
the AIRE gene was performed on ABI-PRISM 377 us-
ing the dye terminator chemistry. Both strands were 
analysed. Precise DNA analysis of our patient allowed 
us to exclude the presence of two hotspot mutations 
(in exons 6 and 8, located between the SAND domain 
and the first PHD finger and in the region coding for 
the first PHD finger, respectively) as well as to identify 
five polymorphisms. Moreover, two mutations (in 1st 
exon 132+1_and 132+3delGTGinsCT) were detected 
(Fig. 1). To establish their cis or in trans configuration, 
direct sequencing of 1st exon was performed on DNA 
from both parents of our patient. We found the same 
two mutations in her mother (132+1_132+3delGTGin-
sCT), but no mutation in her father (Fig. 2). These results 
show that two detected mutations are located in one 
allele of maternal origin. The patient’s mother did not 
present with any clinical symptoms, and in laboratory 
data only the level of aTPO was elevated, while the 
function of the thyroid was normal.
Table III. Results of direct sequencing of the whole coding 
exons of the AIRE gene
Tabela III. Wyniki sekwencjonowania exonów kodujących 
gen AIRE
Exon 
number
Genotype Notes
1 wt/132+1_132+3delGTGinsCT  Results showed on Fig. 1
2 Wt  
3 Wt  
4 Wt  
5  rs 41277544 A/G_rs878081 C/T
6 Wt  
7 Wt  
8 Wt  
9 P355P (CCC > CCT) Silent variant
10 rs60904129 T/C
11 Wt  
12 Wt  
13 Wt  
14 rs1133779 T/C
Figure 1. Results of direct sequencing of 1 exon in the patient’s DNA
Rycina 1. Wyniki sekwencjonowania w exonie 1 DNA pacjentki
Figure 2. Results of direct sequencing of 1 exon in the mother’s DNA
Rycina 2. Wyniki sekwencjonowania w exonie 1 DNA matki
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Discussion
Polyglandular deficiency in our patient affects four 
endocrine glands: parathyroid, thyroid, pituitary gland 
and ovaries, and requires supplementary treatment 
including L-thyroxine, methylprednisolone, oestrogen 
and progesterone. Additionally, non-endocrine defects 
specific for APS I, such as alopecia, vitiligo, keratitis and 
a connective tissue disorder, were diagnosed over the 
course of 12 years of observation. The constellation of 
symptoms, however, does not seem to be specific for 
any known type of APS. Candidiasis, typical for APS I, 
has never been observed and also the early onset would 
not be characteristic for APS II or III [3, 4, 7]. 
In the described case, the whole AIRE gene has been 
sequenced and heterozygous mutation in exon 1 was 
revealed. Since APS is inherited in a recessive manner, 
this change alone is not a cause of the syndrome. How-
ever, DNA sequencing does not allow for detecting 
large gene rearrangements in the coding areas. Thus, 
the possibility that these alterations are present in our 
patient must be taken into account. 
Moreover, the function of polymorphisms found 
in our patient is unknown. In recent literature, in-
creasingly frequent descriptions of rheumatic disor-
ders in the course of APS suggest a potential role of 
the AIRE gene. Recently published data obtained by 
using large-scale genome-wide association (GWA) 
studies indicate a potential role of single nucleotide 
polymorphisms (SNPs) in the AIRE gene in the ae-
tiology of rheumatoid arthritis or lupus erythema-
tosus [8, 9]. The predictive value of the AIRE gene 
in diagnosing patterns of developing autoimmune 
conditions is yet to be determined [10]. 
Although during the 12 years of observation the 
consecutive components of autoimmune polyglandular 
syndrome developed, the level of the known antibodies, 
except aTPO and aTG, remained normal. Therefore, an 
autoimmune process affecting multiple organ systems 
cannot be definitely confirmed. However, a study on 
a group of APS patients in Norway showed that the 
autoimmune background of autoimmune polyglan-
dular syndrome may not, in some cases, be confirmed 
by the presence of the most common autoantibodies 
[9]. Nonetheless, the path of the disorders observed in 
our patient suggests immunosurveillance disturbance 
as the pathogenesis of the symptoms. 
It is possible that in future our patient will develop 
symptoms of other endocrine dysfunctions. The glu-
cocorticoid therapy of connective tissue disease might 
mask, for instance, symptoms of the insufficiency of 
the suprarenal gland. Nevertheless, it is essential that 
the patient remains under strict control in order to 
prevent delayed diagnosis of any additional disorders 
that may occur. 
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